BCANTT 2020: High-risk Non-Muscle Invasive BCG Unresponsive Bladder Cancer: DNA Based Markers

(UroToday.com) Dr. Alexander Wyatt, PhD, Vancouver Prostate Center, and the University of British Columbia, discussed deoxyribonucleic acid (DNA) correlates in bacille Calmette-Guerin (BCG) unresponsive high-risk non-muscle invasive bladder cancer (NMIBC). He discussed recent study findings exploring links between common genomic driver alternations and BCG unresponsiveness.

At median follow-up of 44 months, targeted DNA sequencing, the pre-BCG driver gene alterations were similar to other centers' results. ARID1A mutation status was associated with recurrence with all metachronous tumor pairs having a common ancestor. He observed relatively high but variable changes over time despite having a common ancestral clone (i.e. TERT, TP53, FGFR3). Ongoing genomic driver landscape studies following BCG are needed as genomic drivers pre-BCG is well defined.



Presented by: Alexander Wyatt, BSC, PhD,  Assistant Professor at The University of British Columbia; Senior Research Scientist Vancouver Prostate Center, Vancouver, British Columbia, Canada

Written by: Stephen B. Williams, MD, Medical Director for High-Value Care; Chief of Urology, Professor, Director of Urologic Oncology, Director Urologic Research, The University of Texas Medical Branch at Galveston, TX at the 2020 Virtual Bladder Cancer Advocacy Network Think Tank 2020.
email news signup